Actively Recruiting
A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
Led by Tongji Hospital · Updated on 2024-08-13
150
Participants Needed
1
Research Sites
113 weeks
Total Duration
On this page
Sponsors
T
Tongji Hospital
Lead Sponsor
U
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this observational study is to learn about the treatment effectiveness of physician's choice of chemotherapy and the immune checkpoint inhibitor (ICI)-based therapy in patients with relapsed/refractory ovarian clear cell carcinoma (OCCC), and compare the treatment response with the phase II, single-arm clinical trial INOVA to investigate the efficacy of combinational therapy of sintilimab plus bevacizumab. The main questions it aims to answer are: * What is the efficacy of physician's choice of chemotherapy in relapsed/refractory OCCC patients in the real world? * Is ICI-based therapy more effective than physician's choice of chemotherapy in real-world for relapsed/refractory OCCC patients? * Dose the combinational regimens of sintilimab plus bevacizumab in Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma (INOVA) trial more effective than physician's choice of chemotherapy? Participants will be respectively retrieved and extracted de-identified, longitudinal electronic health records (EHR)-derived data.
CONDITIONS
Official Title
A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients aged 18 to 75 years old
- Histological diagnosis of ovarian clear cell carcinoma
- Recurrent or persistent ovarian clear cell carcinoma with at least one prior line of platinum-containing chemotherapy
- Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less
- Expected survival time of at least 12 weeks
You will not qualify if you...
- Histological evidence of non-ovarian clear cell carcinoma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430030
Actively Recruiting
Research Team
Q
Qinglei Gao, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here